Raymond James Financial Services Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Raymond James Financial Services Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$584K	Buy	5,070 +2,757	+119%	+$378K	﹤0.01%	2511
2024 Q2	$318K	Buy	+2,313	New	+$317K	﹤0.01%	2834
2024 Q1	–	Sell	-8,201	Closed	-$1.08M	–	3457
2023 Q4	$1.08M	Sell	8,201 -5,444	-40%	-$627K	﹤0.01%	1935
2023 Q3	$1.54M	Sell	13,645 -881	-6%	-$92.8K	﹤0.01%	1651
2023 Q2	$1.37M	Buy	14,526 +104	+0.7%	+$10.2K	﹤0.01%	1751
2023 Q1	$1.46M	Buy	14,422 +884	+7%	+$92K	﹤0.01%	1672
2022 Q4	$1.62M	Buy	13,538 +8,962	+196%	+$1.05M	﹤0.01%	1563
2022 Q3	$486K	Buy	+4,576	New	+$464K	﹤0.01%	2264
2018 Q4	–	Sell	-1,917	Closed	-$236K	–	2732
2018 Q3	$236K	Buy	+1,917	New	+$218K	﹤0.01%	2424

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Raymond James Financial Services Advisors's NBIX Position: Q3 2024 in Review

Raymond James Financial Services Advisors increased its Neurocrine Biosciences (NBIX) stake by 119% in Q3 2024, buying an estimated $378K and bringing the position to 5,070 shares worth $584K. The position accounts for ﹤0.01% of the portfolio, ranked #2511.

Raymond James Financial Services Advisors first reported a position in NBIX in Q3 2018 and has held it in 9 quarters since. The position peaked at $1.62M in Q4 2022. 575 funds tracked by Wall St. Rank hold NBIX as of Q3 2024.

Raymond James Financial Services Advisors held 5,070 shares of Neurocrine Biosciences worth $584K as of Q3 2024.
Raymond James Financial Services Advisors bought 2,757 Neurocrine Biosciences shares in Q3 2024, an estimated $378K.
Neurocrine Biosciences made up ﹤0.01% of Raymond James Financial Services Advisors's portfolio in Q3 2024, its #2511 holding.
Raymond James Financial Services Advisors first reported a position in Neurocrine Biosciences in Q3 2018 and has held it in 9 quarters since.
Raymond James Financial Services Advisors's Neurocrine Biosciences position peaked at $1.62M in Q4 2022.
575 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2024.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2024, filed 18 Oct 2024.